Sino Biopharmaceutical climbs on FDA approval for cancer drug trial
04/09/2026 04:16
BUZZ-Sino Biopharmaceutical climbs on FDA approval for cancer drug trial ** Shares of Sino Biopharmaceutical 1177.HK climb 2.7% to HK$5.74, their highest level since August 27
** Stock on track for a third consecutive session of gains, if current trend holds
** The Chinese pharmaceutical group says the U.S. Food and Drug Administration (FDA) grants investigational new drug approval for clinical trial on TQB6426 "GPC3 antibody-drug conjugate" for advanced malignant tumours
** The company says it will accelerate the Phase I clinical trial of TQB6426 to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy in patients with advanced malignant tumours
** YTD, stock down 9%, while Hang Seng Biotech Index .HSBIO up 11.9%
(Reporting by Donny Kwok)
Recent news on Sino Biopharmaceutical
See all newsHong Kong stocks end higher on pharma, tech gains
Hong Kong stocks climb, led by pharmaceutical, tech stocks
Brief: Sino Biopharmaceutical Says China's CDE Accepts NDA For TQH2722 Injection
Brief: Sino Biopharmaceutical China CDE Accepts New Drug Application For TQB2102 Injection
Sino Biopharmaceutical climbs on plan to raise stake in core unit